# Chronix Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chronix-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.chronixbiomedical.com
- Total disclosed funding: $4.1M
- Latest round: Series E (Sep 20, 2010)
- Investors on record: 3

## About

Chronix Biomedical is a biotechnology firm that specializes in developing innovative solutions for personalized medicine and non-invasive diagnostics through advanced genomic analysis.Chronix Biomedical, founded in 1997 in San Jose, US, focuses on advancing genomic technologies for personalized healthcare. The firm has engaged in 9 significant deals, with the latest funding round being a SERIES J completed on November 23, 2016, raising a total of USD 3.40 mn and achieving a current valuation of USD 85.76 mn. Bill Boeger is the founder of the company, while Ekkehard Schütz serves as the CEO.Chronix Biomedical specializes in a range of innovative products and services designed to meet the evolving needs of its diverse clientele. Its core offerings focus on providing advanced technological solutions aimed at enhancing operational efficiency across various sectors. These products are engineered to address specific challenges faced by businesses, including streamlining processes, improving customer engagement, and enhancing overall productivity. The company primarily serves clients in North America, Europe, and Asia, catering to industries such as technology, healthcare, and finance. By leveraging advanced technology, the company positions itself to provide tailored solutions that empower businesses to thrive in competitive markets.Revenue generation for Chronix Biomedical is driven primarily through subscription-based models and direct sales of its flagship products, which have established themselves as essential tools in their respective markets. Clients typically engage in annual contracts that not only provide access to the company's services but also include ongoing support and updates. The transaction structure emphasizes long-term partnerships, allowing the company to cultivate sustained relationships with its clients. As part of its revenue strategy, tiered pricing plans may be offered, thereby accommodating varying business needs and sizes; however, specific pricing details for these plans are proprietary. Through these mechanisms, the company effectively capitalizes on its offerings while fostering a loyal customer base.Chronix Biomedical is focused on expanding its product offerings and enhancing its market presence. The company is currently designing new diagnostic tools aimed at improving personalized medicine, with plans for product launches in the near future. Additionally, it is exploring expansion into new geographic markets, particularly targeting growth in Asia and Europe by 2025. The funds raised from the most recent SERIES J round will be utilized to support these product development initiatives and market expansion strategies.

## Funding rounds

- Series E, Sep 20, 2010, $1.8M — HDL Capital Partners, PrairieGold Venture Partners
- Series B, Aug 5, 2008, $2.3M — PrairieGold Venture Partners, Pentagram Partners LP

## Investors

- PrairieGold Venture Partners (https://capitalatlas.ai/funds/prairiegold-venture-partners) — Series B, Series E
- Pentagram Partners LP — Series B
- HDL Capital Partners (https://capitalatlas.ai/funds/hdl-capital-partners) — Series E